Myeloid Cell Leukemia 1 Inhibitor
Showing 1 - 25 of >10,000
Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)
Not yet recruiting
- Acute Myeloid Leukemia
- Lymphoma, Mantle-Cell
- (no location specified)
Dec 22, 2022
Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation Trial (Biospecimen Collection, Bone
Not yet recruiting
- Acute Myeloid Leukemia With KMT2A Rearrangement
- Acute Myeloid Leukemia With NPM1 Mutation
- Biospecimen Collection
- +7 more
- (no location specified)
Jun 1, 2023
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Active, not recruiting
- Acute Lymphoblastic Leukemia
- +15 more
- Laboratory Biomarker Analysis
- +3 more
-
Chicago, Illinois
- +2 more
Jan 12, 2023
Acute Myeloid Leukemia Trial in Nashville (Biopsy of Bone, Cytarabine, Daunorubicin)
Recruiting
- Acute Myeloid Leukemia
- Biospecimen Collection
- +5 more
-
Buffalo, New York
- +1 more
Jan 27, 2023
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer Trial in Cleveland (Vactosertib, Fludarabine Phosphate,
Recruiting
- Colorectal Cancer
- +11 more
- Vactosertib
- +4 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Jan 18, 2023
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia Trial in United States (BMF-500)
Not yet recruiting
- Acute Myeloid Leukemia
- +2 more
-
Los Angeles, California
- +9 more
Jun 27, 2023
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related
Active, not recruiting
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +2 more
- Cytarabine
- +4 more
-
Tucson, Arizona
- +2 more
Aug 5, 2022
Acute Myeloid Leukaemia Trial in Worldwide (S 64315 (also referred as MIK665) and azacitidine)
Active, not recruiting
- Acute Myeloid Leukaemia
- S 64315 (also referred as MIK665) and azacitidine
-
Houston, Texas
- +6 more
Dec 16, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Trial in United States
Suspended
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Cytarabine
- +2 more
-
Los Angeles, California
- +5 more
Dec 10, 2022
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- (no location specified)
Nov 9, 2023
Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia Trial in Boston (Cytokine-Induced Memory-like Natural Killer
Not yet recruiting
- Acute Myeloid Leukemia
- +3 more
- Cytokine-Induced Memory-like Natural Killer Cells
- +2 more
-
Boston, Massachusetts
- +1 more
Nov 22, 2023
Acute Myeloid Leukemia Trial in Miami (CPX-351, Midostaurin, Busulfan)
Recruiting
- Acute Myeloid Leukemia
- CPX-351
- +5 more
-
Miami, FloridaMiami Cancer Institute at Baptist Health of South Florida
Jul 27, 2022
Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Chicago (Laboratory Biomarker
Completed
- Acute Myeloid Leukemia
- +4 more
- Laboratory Biomarker Analysis
- Selinexor
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
May 12, 2021
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine,
Active, not recruiting
- Acute Myeloid Leukemia
- +5 more
- Decitabine
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Acute Myeloid Leukemia, MDS, Myeloid Malignancies Trial in Boston (Decitabine, Filgrastim)
Not yet recruiting
- Acute Myeloid Leukemia
- +6 more
-
Boston, Massachusetts
- +1 more
Mar 31, 2023
Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in
Completed
- Relapsed or Refractory Haematological Malignancies Including
- +10 more
-
Aachen, Germany
- +11 more
Oct 21, 2021
Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted
Recruiting
- Acute Myeloid Leukemia
- +3 more
- CD123 targeted CAR-NK cells
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Aug 28, 2023
AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- CD33/CLL1 dual CAR-NK cell
- +5 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 4, 2023
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (STAT
Active, not recruiting
- Acute Myeloid Leukemia
- +2 more
- STAT Inhibitor OPB-111077
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Dec 20, 2022
Myeloid Malignancy, Acute Myeloid Leukemia Trial in Cleveland (Venetoclax, Decitabine)
Not yet recruiting
- Myeloid Malignancy
- Acute Myeloid Leukemia
-
Cleveland, OhioUniversity Hospitals Seidman Cancer, Case Comprehensive Cancer C
Nov 8, 2023
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti Tim-3/CD123 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 4, 2023